首頁 > 市場調查報告書 > 製藥

眼科藥物

青光眼市場規模、佔有率和成長分析（按類型、藥物類別、給藥途徑、最終用途、通路和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1900273

青光眼市場規模、佔有率和成長分析（按類型、藥物類別、給藥途徑、最終用途、通路和地區分類）－2026-2033年產業預測

Glaucoma Market Size, Share, and Growth Analysis, By Type (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG)), By Drug Class, By Administration, By End Use, By Distribution, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，青光眼市場規模將達到 87 億美元，到 2025 年將成長至 91.9 億美元，到 2033 年將成長至 142.1 億美元，在預測期（2026-2033 年）內，複合年成長率為 5.6%。

由於這種慢性眼科疾病的盛行率不斷上升，全球青光眼市場正經歷顯著成長。青光眼若不及時治療，可能導致不可逆的視力喪失。人口老化和慢性眼科疾病發生率的上升進一步推動了市場擴張。診斷和治療方法的創新，包括微創手術技術和先進的雷射治療，正在推動市場動態。然而，高昂的治療費用和某些地區醫療資源匱乏等挑戰阻礙了市場成長。該市場的主要特徵是主要企業之間的激烈競爭，促使他們不斷進行研發，以開發尖端的青光眼治療方案。總體而言，人們意識的提高以及診斷和治療方案的改進預計將維持市場成長勢頭。

青光眼市場促進因素

推動青光眼市場發展的關鍵因素是全球眼科疾病的上升。人口老化，加上糖尿病和高血壓等慢性疾病的增加，導致青光眼病例的發生率不斷上升。由於青光眼是導致不可逆性失明的主要原因之一，因此早期發現、準確診斷和有效治療的需求更加迫切。這種日益成長的認知和需求推動了對尖端青光眼治療方案的需求，包括先進的診斷設備、有效的藥物療法和先進的手術技術，以應對這一嚴重的健康問題。

青光眼市場限制因素

青光眼市場面臨的一大挑戰是許多地區對青光眼的認知不足，以及常規篩檢的實施不力。由於青光眼早期通常無症狀，定期眼科檢查對於有效診斷至關重要。公眾和醫療服務提供者對青光眼的認知不足會導致診斷和治療延誤，最終造成本可避免的視力喪失。此外，治療青光眼帶來的沉重經濟負擔（包括藥物、手術和後續後續觀察的費用）也成為患者獲得治療的一大障礙，尤其對於中低收入者更是如此。

青光眼市場趨勢

全球青光眼市場正呈現出顯著的趨勢，即採用尖端診斷技術和創新治療方案。人們對青光眼可能導致不可逆視力喪失的認知不斷提高，促使人們更加關注早期發現和治療策略。這一趨勢的特點是整合了先進的診斷成像工具，例如光同調斷層掃瞄（OCT）、視野檢查和先進的眼壓測量技術。這些技術提高了青光眼診斷和後續觀察的準確性，使醫療服務提供者能夠及時採取干涉措施。因此，預計這一市場轉變將改善患者的治療效果，並有助於提升青光眼治療水平。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較

主要企業簡介

Aerie Pharmaceuticals（USA）
Akorn, Inc.（USA）
AbbVie Inc.（USA）
Bausch Health Companies Inc.（Canada）
Inotek Pharmaceuticals Corp.（USA）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
Pfizer Inc.（USA）
Santen Pharmaceutical Co., Ltd.（Japan）
Glaukos Corporation（USA）
Ocular Therapeutix, Inc.（USA）
Santen Inc.（Japan）
Ono Pharmaceutical Co., Ltd.（Japan）
Nicox SA（France）
Sun Pharmaceutical Industries Ltd.（India）
Visiox Pharma（USA）
TearClear（USA）
MediPrint Ophthalmics（formerly Leo Lens Pharma）（Denmark）
Tarsier Pharma（USA）
Peregrine Ophthalmic（USA）

結論與建議

簡介目錄

Product Code: SQMIG35A2274

Glaucoma Market size was valued at USD 8.7 Billion in 2024 and is poised to grow from USD 9.19 Billion in 2025 to USD 14.21 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The global glaucoma market is experiencing notable growth fueled by an increase in the prevalence of this chronic eye condition, which can result in irreversible vision loss if untreated. The aging population and the rising occurrence of chronic eye ailments further contribute to market expansion. Innovations in diagnostics and treatment, including minimally invasive surgical techniques and advanced laser therapies, are enhancing market dynamics. Nonetheless, challenges such as high treatment costs and inadequate healthcare access in certain areas present obstacles to growth. The landscape is marked by intense competition among leading players, prompting continuous research and development to produce cutting-edge glaucoma management solutions. Overall, heightened awareness and improved diagnostic and therapeutic options are anticipated to sustain market momentum.

Top-down and bottom-up approaches were used to estimate and validate the size of the Glaucoma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Glaucoma Market Segments Analysis

Global Glaucoma Market is segmented by type, drug class, administration, end use, distribution and region. Based on type, the market is segmented into closed angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and others. Based on drug class, the market is segmented into beta blockers, prostaglandins, alpha adrenergic agonist, carbonic anhydrase inhibitors, combination drugs and others. Based on administration, the market is segmented into oral, injections, intravitreal and other. Based on end use, the market is segmented into hospitals, specialty centers and others. Based on distribution, the market is segmented into hospital, online and retail. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Glaucoma Market

A significant factor propelling the glaucoma market is the rising global prevalence of this ocular condition. The aging demographic, alongside the increase in chronic health issues such as diabetes and hypertension, has led to a higher incidence of glaucoma cases. Given that glaucoma is a primary cause of irreversible blindness, the urgency for timely detection, accurate diagnosis, and effective treatment has intensified. This heightened awareness and necessity spur the demand for cutting-edge glaucoma management options, encompassing sophisticated diagnostic equipment, effective pharmacological therapies, and advanced surgical techniques to address this critical health concern.

Restraints in the Glaucoma Market

A significant challenge facing the glaucoma market is the widespread lack of awareness and inadequate routine screening practices for this condition in numerous areas. Since glaucoma frequently remains asymptomatic during its early phases, effective diagnosis relies heavily on consistent eye examinations. This knowledge gap among both the public and healthcare providers can lead to delays in diagnosis and intervention, which may ultimately result in preventable vision impairment. Furthermore, the substantial financial burden associated with managing glaucoma-encompassing the costs of medications, surgical procedures, and ongoing follow-up care-represents a critical barrier to accessibility, particularly for individuals in low- and middle-income regions.

Market Trends of the Glaucoma Market

The global glaucoma market is witnessing a significant trend towards the adoption of cutting-edge diagnostic technologies and innovative treatment solutions. As awareness of glaucoma's potential to cause irreversible vision loss rises, there is an intensified focus on early detection and management strategies. This trend is characterized by the integration of advanced imaging and diagnostic tools, including optical coherence tomography (OCT), visual field assessments, and sophisticated tonometry techniques. These technologies enhance the accuracy of glaucoma diagnosis and ongoing monitoring, enabling healthcare providers to implement timely interventions. Consequently, this market shift is expected to improve patient outcomes and elevate the standard of care in glaucoma management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Glaucoma Market Size by Type & CAGR (2026-2033)

Market Overview
Closed Angle Glaucoma (CAG)
Open Angle Glaucoma (OAG)
Secondary Glaucoma
Congenital Glaucoma
Others

Global Glaucoma Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Beta Blockers
Prostaglandins
Alpha Adrenergic Agonist
Carbonic Anhydrase Inhibitors
Combination Drugs
Others

Global Glaucoma Market Size by Administration & CAGR (2026-2033)

Market Overview
Oral
Injections
Intravitreal
Other

Global Glaucoma Market Size by End Use & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Centers
Others

Global Glaucoma Market Size by Distribution & CAGR (2026-2033)

Market Overview
Hospital
Online
Retail

Global Glaucoma Market Size & CAGR (2026-2033)

North America (Type, Drug Class, Administration, End Use, Distribution)
- US
- Canada
Europe (Type, Drug Class, Administration, End Use, Distribution)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Administration, End Use, Distribution)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Administration, End Use, Distribution)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Administration, End Use, Distribution)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Aerie Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Akorn, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inotek Pharmaceuticals Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glaukos Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ono Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nicox S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Visiox Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TearClear (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediPrint Ophthalmics (formerly Leo Lens Pharma) (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tarsier Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Peregrine Ophthalmic (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments